As monotherapy it is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) positive for the anaplastic lymphoma kinase (ALK), previously treated with crizotinib.

Manufacturer – NOVARTIS
Specialty – Oncology
Active principle – Ceritinib